|
Real-time Estimate
Cboe BZX
21:54:49 02/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 23.86 USD | +0.44% |
|
-5.53% | -18.22% |
| 08-25 | Oruka Therapeutics Names Chief Commercial Officer | MT |
| 08-20 | Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis | MT |
| Market Cap | 2.99B 2.58B 2.43B 2.21B 4.13B 282B 4.16B 28.72B 11.15B 144B 11.21B 10.96B 474B | P/E 2026 * |
61.2x | P/E 2027 * | 19x |
|---|---|---|---|---|---|
| Enterprise Value | 2.7B 2.33B 2.19B 2B 3.73B 255B 3.76B 25.95B 10.07B 130B 10.13B 9.91B 428B | EV / Sales 2026 * |
5.02x | EV / Sales 2027 * | 3.42x |
| Free-Float |
98.22% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Arcutis Biotherapeutics, Inc.
| 1 day | +0.63% | ||
| 1 week | -5.53% | ||
| Current month | -0.92% | ||
| 1 month | -8.44% | ||
| 3 months | +14.24% | ||
| 6 months | -4.08% | ||
| Current year | -18.22% |
| 1 week | 23.21 |  | 25.15 |
| 1 month | 23.21 | | 29.24 |
| Current year | 19.3 | | 30.75 |
| 1 year | 15.13 | | 31.77 |
| 3 years | 1.76 | | 31.77 |
| 5 years | 1.76 | | 31.77 |
| 10 years | 1.76 | | 40.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Todd Watanabe
CEO | Chief Executive Officer | 58 | 01/04/2017 |
| Corporate Officer/Principal | 71 | 03/12/2025 | |
Latha Vairavan
DFI | Director of Finance/CFO | - | 15/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick Heron
CHM | Chairman | 55 | 01/12/2019 |
Todd Watanabe
BRD | Director/Board Member | 58 | 01/01/2016 |
Howard Welgus
BRD | Director/Board Member | 74 | 01/08/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/08/26 | Exercice | Director | 114,600 | 0.0916% | ||
| 20/08/26 | Exercice | Director | 3,216 | 0.0026% | ||
| 19/08/26 | Sell | Chief Technology Officer | -1,697 | 0.0014% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.44% | -5.53% | +55.03% | +186.84% | 2.99B | |
| +3.10% | +3.95% | +46.57% | +2.93% | 82.26B | |
| -3.20% | -0.60% | +515.00% | +36.04% | 61.59B | |
| +0.89% | +0.12% | -17.32% | -35.39% | 59.05B | |
| -1.25% | -5.30% | -1.98% | +33.18% | 51.23B | |
| +0.92% | -0.23% | +11.50% | +169.82% | 48.3B | |
| +3.45% | +0.50% | +59.12% | -16.57% | 31.92B | |
| +2.08% | -0.71% | +47.96% | +101.04% | 25.34B | |
| +0.20% | +1.70% | -3.42% | +190.03% | 22.56B | |
| -0.52% | -1.98% | +65.45% | +110.84% | 16.56B | |
| Average | +0.63% | -2.70% | +77.79% | +77.88% | 40.18B | |
| Weighted average by Cap. | +0.63% | -2.78% | +97.70% | +47.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 537M 463M 436M 398M 743M 50.72B 749M 5.17B 2B 25.93B 2.02B 1.97B 85.19B | 686M 591M 557M 508M 949M 64.76B 956M 6.6B 2.56B 33.11B 2.57B 2.52B 109B |
| Net income | 51.79M 44.68M 42.09M 38.35M 71.68M 4.89B 72.22M 498M 193M 2.5B 194M 190M 8.22B | 168M 145M 136M 124M 232M 15.86B 234M 1.62B 627M 8.11B 630M 617M 26.64B |
| Net Debt | -288M -249M -234M -214M -399M -27.24B -402M -2.77B -1.08B -13.93B -1.08B -1.06B -45.75B | -638M -550M -518M -472M -883M -60.25B -889M -6.14B -2.38B -30.8B -2.39B -2.34B -101B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | $23.75 | 0.00% | 828,228 |
| 01/09/26 | $23.75 | -0.92% | 1,101,734 |
| 31/08/26 | $23.97 | +0.80% | 1,522,731 |
| 28/08/26 | $23.78 | -4.38% | 1,536,018 |
| 27/08/26 | $24.87 | -1.07% | 2,204,696 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ARQT Stock
Select your edition
All financial news and data tailored to specific country editions
